SMC
AVNS

Smith, Moore & Co’s Avanos Medical AVNS Stock Holding History

Smith, Moore & Co’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,751
Closed -$283K – 172
2015
Q1 		$283K Sell
5,751
-211
-4% -$9.77K 0.15% 130
2014
Q4 		$271K Buy
+5,962
New +$234K 0.14% 129

Other funds holding AVNS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return
RP
RR Partners New York $929M AUM 110.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Smith, Moore & Co's AVNS Position: Q2 2015 in Review

Smith, Moore & Co sold out of Avanos Medical (AVNS) in Q2 2015, closing a stake of 5,751 shares — an estimated $283K sold.

Smith, Moore & Co first reported a position in AVNS in Q4 2014 and held it in 2 quarters. The position peaked at $283K in Q1 2015. 419 funds tracked by Wall St. Rank hold AVNS as of Q2 2015.

  • Smith, Moore & Co reported no remaining Avanos Medical position as of Q2 2015 after selling out during the quarter.
  • Smith, Moore & Co sold 5,751 Avanos Medical shares in Q2 2015, an estimated $283K.
  • Smith, Moore & Co first reported a position in Avanos Medical in Q4 2014 and held it in 2 quarters.
  • Smith, Moore & Co's Avanos Medical position peaked at $283K in Q1 2015.
  • 419 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2015.

Based on Smith, Moore & Co's 13F filing for Q2 2015, filed 31 Jul 2015.